

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant (s): Navid Malik et al.

Serial No.: NA


Group Art Unit: NA

Filed: Concurrently herewith

Examiner: NA

For: A DENDRITIC-ANTINEOPLASTIC DRUG DELIVERY SYSTEM

jc564 U.S. PTO
10/016733
10/29/01

EXPRESS MAILING LABEL NO. EL83683022708
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL WITH SUFFICIENT POSTAGE IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231, ON:
October 29, 2001
DATE OF DEPOSIT
Melissa Wagner
PRINT OR TYPE NAME OF PERSON SIGNING CERTIFICATE

SIGNATURE OF PERSON SIGNING CERTIFICATE
October 29, 2001
DATE OF SIGNATURE

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to Applicant's duty of disclosure under 37 CFR §1.56, the
Examiner's attention is directed to the information identified in the attached Form
PTO 1449.

A copy of all cited patents and printed publications is enclosed. The
Examiner is requested to review each reference and formulate his own understanding
thereof.

Respectfully submitted,


Karen L. Kimble
Registration No. 26,995
Phone: (989) 636-1687

P. O. Box 1967
Midland, MI 48641-1967

KLK/maw

INFORMATION DISCLOSURE STATEMENT

(Use Several Sheets if necessary)

ATTY DOCKET NO.

60800B

SERIAL NO.

NA

APPLICANT

Navid Malik et al.

FILING DATE

NA

GROUP

NA

CS64 U.S. PTO
10/016733



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
		5,527,524	6/98	Tomalia et al.	424	1.33	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES I NO

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, Place of Publication, Etc.)

		Esfand, et al., "Poly(amidoamine) (PAMAM) Dendrimers: from Biomimicry to Drug Delivery and Biomedical Applications", DDT Vol. 6, Number 8, pp.427-436 (April 2001).
		Malik, et al., "Dendrimer-Platinate: A Novel Approach to Cancer Chemotherapy", ANTI-CANCER DRUGS, 10, pp. 767-776 (1999).
		Ohndorf, et al., "Basis for Recognition of Cisplatin-Modified DNA by High-Mobility-Group Proteins", LETTERS TO NATURE, Vol. 299, pp. 708-712, (June 1999).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to Applicant.